Opinion

Video

Moving Beyond the Joint: The Interplay Between Gout and Kidney Disease

Author(s):

Nehad Soloman, MD, FACR,Andrew Sharobeem, DO, FACR

Nehad Soloman, MD, FACR; Andrew Sharobeem, DO, FACR, and Sunil Patel, MD, explore the nephrologist's vital role in gout diagnosis, treatment options for gout patients with chronic kidney disease, and strategies for managing refractory gout and its associated challenges.

Related Videos
Yehuda Handelsman, MD: Insulin Resistance in Cardiometabolic Disease and DCRM 2.0 | Image Credit: TMIOA
Christine Frissora, MD | Credit: Weill Cornell
Hope on the Horizon: 2 Food Allergy Breakthroughs in 2024
4 experts are featured in this series.
4 experts are featured in this series.
4 experts are featured in this series.
4 experts are featured in this series.
Steven Fein, MD | Credit: University of Michigan
Related Content
Iain B. McInnes, MBChB I Credit: University of Glasgow
December 21st 2024

Guselkumab 100 mg Every 8 Weeks Consistently Improves Joint, Skin Through Week 24

Chelsie Derman
Diabetes Dialogue: Celebrating 2024 - The Year of the Continuous Glucose Monitor
December 16th 2024

Diabetes Dialogue: Celebrating 2024 - The Year of the Continuous Glucose Monitor

Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES Natalie Bellini, DNP, FNP-BC, BC-ADM, CDCE
Advancing the Diagnostic Criteria for Multiple Sclerosis: A New Era of Early Detection and Precision | HCPLive.com
December 21st 2024

Advancing the Diagnostic Criteria for Multiple Sclerosis: A New Era of Early Detection and Precision

Isabella Ciccone, MPH
Irl Hirsch, MD | Credit: University of Washington
December 12th 2024

Diabetes Dialogue: Celebrating 25 Years of CGM, with Irl Hirsch, MD

Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES Natalie Bellini, DNP, FNP-BC, BC-ADM, CDCE
FDA Approves Tirzepatide for Obstructive Sleep Apnea in Obesity | Image Credit: US Food and Drug Administration
December 20th 2024

FDA Approves Tirzepatide for Obstructive Sleep Apnea in Obesity

Connor Iapoce
FDA logo in black over a white background. | Credit: US Food and Drug Administration
December 20th 2024

FDA Issues CRL for Sotagliflozin in Type 1 Diabetes and CKD

Patrick Campbell
© 2024 MJH Life Sciences

All rights reserved.